Talphera Stock Today
| TLPH Stock | 0.72 0.04 5.26% |
Performance0 of 100
| Odds Of DistressOver 84
|
Talphera is trading at 0.72 as of the 29th of November 2024. This is a 5.26% down since the beginning of the trading day. The stock's open price was 0.76. Talphera has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Talphera symbol was changed from ACRX on 10th of January 2024. Equity ratings for Talphera are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of February 2011 | Category Healthcare | Classification Health Care |
Teliphone Corporation, a telecommunications company, offer voice, data, and cloud services in Canada. The company has 16.99 M outstanding shares of which 85.55 K shares are at this time shorted by private and institutional investors with about 1.46 trading days to cover. More on Talphera
Moving together with Talphera Stock
| 0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Talphera Stock
Talphera Stock Highlights
| Older Symbol | ACRX | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CEO Director | Vincent Angotti | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Talphera can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Talphera's financial leverage. It provides some insight into what part of Talphera's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Talphera (TLPH) is traded on NASDAQ Exchange in USA. It is located in 1850 Gateway Drive, San Mateo, CA, United States, 94404 and employs 15 people. Talphera was previously known as AcelRx Pharmaceuticals and was traded on NASDAQ Exchange under the symbol ACRX. Talphera is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.29 M. Talphera conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 16.99 M outstanding shares of which 85.55 K shares are at this time shorted by private and institutional investors with about 1.46 trading days to cover.
Talphera currently holds about 90.29 K in cash with (17.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Talphera Probability Of Bankruptcy
Ownership AllocationTalphera shows a total of 16.99 Million outstanding shares. 30% of Talphera outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Talphera Ownership Details
Talphera Historical Income Statement
Talphera Stock Against Markets
Talphera Corporate Executives
Elected by the shareholders, the Talphera's board of directors comprises two types of representatives: Talphera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Talphera. The board's role is to monitor Talphera's management team and ensure that shareholders' interests are well served. Talphera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Talphera's outside directors are responsible for providing unbiased perspectives on the board's policies.
When determining whether Talphera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Talphera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Talphera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Talphera Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Talphera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Talphera Stock please use our How to Invest in Talphera guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Talphera. If investors know Talphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Talphera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Revenue Per Share 0.018 | Return On Assets (0.47) | Return On Equity (1.18) |
The market value of Talphera is measured differently than its book value, which is the value of Talphera that is recorded on the company's balance sheet. Investors also form their own opinion of Talphera's value that differs from its market value or its book value, called intrinsic value, which is Talphera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Talphera's market value can be influenced by many factors that don't directly affect Talphera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Talphera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Talphera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Talphera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.